 Skye Bioscience Inc OTCQB:SKYE said it has started screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion SBI-100 OE, a proprietary, synthetic cannabinoid derivative intended to treat glaucoma. San Diego-based Skye said this study has received all regulatory approvals to initiate in Australia and that it will be conducted at CMAX Clinical Research, the companys contract clinical trial unit in Adelaide, Australia. 